Arrhythmias & electrophysiology
Safety and performance of conduction system pacing: Real-world experience from a product surveillance registry
Authors' conclusion
In a multicenter cohort of LBBAP and HBP patients treated with the catheter-delivered 3830 lead, lead-related complication rates were low and electrical parameters were stable through 30 months.
Study context
- Population
- Patients undergoing pacemaker implantation for conduction system pacing (CSP) with Medtronic 3830 lead, Medtronic product surveillance registry (PSR), 77 centres, Jan 2019–Dec 2023
- Participants
- 2,342 patients · 77 centres
- Exposure
- Left bundle branch area pacing (LBBAP) vs His-bundle pacing (HBP) with the Medtronic 3830 lead
- LBBAPn = 1,502
- HBPn = 840reference
- Outcome
- Lead-related complications and pacing capture threshold
Methodological detailsmulticentre, product surveillance registry
- Multicentre
- Product surveillance registry
Main finding
As reported in the abstract
Lead complication rate · 36 months postimplant
- LBBAP had lower pacing thresholds than HBP through 30 months
- P < 0.001
Observational data: associations, not effects.
Further findings
R-wave sensing and impedance · through 30 months
- LBBAP had higher R-wave sensing and higher impedance than HBP
- P < 0.001
All-cause mortality · 36 months
- No difference in all-cause mortality
Original publication
Safety and performance of conduction system pacing: Real-world experience from a product surveillance registry. Heart Rhythm. Published 3 July 2024. doi:10.
Summarised from the published abstract; every number is checked against it